298 related articles for article (PubMed ID: 26373957)
1. Pharmacokinetic and pharmacodynamic considerations for the next generation protein therapeutics.
Shah DK
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):553-71. PubMed ID: 26373957
[TBL] [Abstract][Full Text] [Related]
2. Tools for predicting the PK/PD of therapeutic proteins.
Diao L; Meibohm B
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1115-25. PubMed ID: 25936400
[TBL] [Abstract][Full Text] [Related]
3. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
Singh AP; Shin YG; Shah DK
Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
[TBL] [Abstract][Full Text] [Related]
4. Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates.
Li C; Chen SC; Chen Y; Girish S; Kaagedal M; Lu D; Lu T; Samineni D; Jin JY
J Clin Pharmacol; 2020 Oct; 60 Suppl 1(Suppl 1):S105-S119. PubMed ID: 33205423
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and ADME characterizations of antibody-drug conjugates.
Lin K; Tibbitts J; Shen BQ
Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological considerations for predicting PK/PD at the site of action for therapeutic proteins.
Wang W; Zhou H
Drug Discov Today Technol; 2016; 21-22():35-39. PubMed ID: 27978986
[TBL] [Abstract][Full Text] [Related]
7. PK-PD modeling of protein drugs: implications in assay development.
Roskos LK; Schneider A; Vainshtein I; Schwickart M; Lee R; Lu H; Faggioni R; Liang M
Bioanalysis; 2011 Mar; 3(6):659-75. PubMed ID: 21417734
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.
Wang YM; Jawa V; Ma M
Bioanalysis; 2014 Jan; 6(1):79-87. PubMed ID: 24341496
[TBL] [Abstract][Full Text] [Related]
9. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
Sapra P; Betts A; Boni J
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
[TBL] [Abstract][Full Text] [Related]
10. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
Zhao L; Shang EY; Sahajwalla CG
J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
Kamath AV; Iyer S
Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
[TBL] [Abstract][Full Text] [Related]
12. Design of next-generation protein therapeutics.
Caravella J; Lugovskoy A
Curr Opin Chem Biol; 2010 Aug; 14(4):520-8. PubMed ID: 20638324
[TBL] [Abstract][Full Text] [Related]
13. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.
Meibohm B; Derendorf H
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):401-13. PubMed ID: 9352388
[TBL] [Abstract][Full Text] [Related]
14. Systems pharmacology and enhanced pharmacodynamic models for understanding antibody-based drug action and toxicity.
Ait-Oudhia S; Ovacik MA; Mager DE
MAbs; 2017 Jan; 9(1):15-28. PubMed ID: 27661132
[TBL] [Abstract][Full Text] [Related]
15. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
Agoram BM; Martin SW; van der Graaf PH
Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
[TBL] [Abstract][Full Text] [Related]
16. Are Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical Challenges.
Schadt S; Hauri S; Lopes F; Edelmann MR; Staack RF; Villaseñor R; Kettenberger H; Roth AB; Schuler F; Richter WF; Funk C
Drug Metab Dispos; 2019 Dec; 47(12):1443-1456. PubMed ID: 31748266
[TBL] [Abstract][Full Text] [Related]
17. Adapting ADME and Pharmacokinetic Analysis to the Next Generation of Therapeutic Modalities.
Hochman JH
J Pharm Sci; 2021 Jan; 110(1):35-41. PubMed ID: 33049260
[TBL] [Abstract][Full Text] [Related]
18. Mathematical Models to Characterize the Absorption, Distribution, Metabolism, and Excretion of Protein Therapeutics.
Liu S; Shah DK
Drug Metab Dispos; 2022 Jun; 50(6):867-878. PubMed ID: 35197311
[TBL] [Abstract][Full Text] [Related]
19. The biodistribution of therapeutic proteins: Mechanism, implications for pharmacokinetics, and methods of evaluation.
Conner KP; Devanaboyina SC; Thomas VA; Rock DA
Pharmacol Ther; 2020 Aug; 212():107574. PubMed ID: 32433985
[TBL] [Abstract][Full Text] [Related]
20. Key Physicochemical Characteristics Influencing ADME Properties of Therapeutic Proteins.
Jing X; Hou Y; Hallett W; Sahajwalla CG; Ji P
Adv Exp Med Biol; 2019; 1148():115-129. PubMed ID: 31482497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
